Comparative Pharmacology
Head-to-head clinical analysis: PROCALAMINE versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROCALAMINE versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
PROCALAMINE vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Procalamine is a combination of antihistamines (chlorpheniramine and pheniramine) and a sympathomimetic (phenylephrine). Chlorpheniramine and pheniramine are histamine H1 receptor antagonists, blocking the effects of histamine, while phenylephrine is an alpha-1 adrenergic receptor agonist causing vasoconstriction.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% is a crystalline amino acid solution combined with electrolytes and dextrose. Amino acids provide substrates for protein synthesis, dextrose supplies calories to minimize protein catabolism, and electrolytes maintain acid-base and electrolyte balance.
Intravenous: 1.5 g/kg ideal body weight (IBW) over 12-24 hours; maximal rate: 0.625 g/kg/hour.
Intravenous infusion: 500-1000 mL administered over 1-2 hours per day, adjusted based on electrolyte and fluid requirements. Typical adult dose provides 2.75% amino acids and 5% dextrose with electrolytes.
None Documented
None Documented
2.5–3.5 hours in healthy adults; prolonged in renal impairment (up to 20–30 hours in ESRD).
Amino acids: 15-30 min (rapid redistribution). Dextrose: 1-2 h. Clinical context: continuous infusion maintains steady state.
Primarily renal; >95% of the dose excreted unchanged in urine within 24 hours. Minimal biliary/fecal elimination (<5%).
Renal: >95% of infused amino acids and dextrose metabolites excreted as urea, CO2, and water. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution